Crossmark

Pharmacological and structural insights into nanvuranlat, a selective LAT1 (SLC7A5) inhibitor, and its N-acetyl metabolite with implications for cancer therapy

Crossref DOI link: https://doi.org/10.1038/s41598-025-87522-6

Published Online: 2025-01-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jin, Chunhuan

Zhou, Xinyu

Xu, Minhui

Okanishi, Hiroki

Ohgaki, Ryuichi

Kanai, Yoshikatsu
Funding

Funding for this research was provided by:

Japan Society for the Promotion of Science (23K19451, 19H03407)

Japan Agency for Medical Research and Development Project (JP19cm0106151)

J-Pharma Co., Ltd
License Information

Text and Data Mining valid from 2025-01-23

Version of Record valid from 2025-01-23
More Information

Article History

Received: 2 November 2024

Accepted: 20 January 2025

First Online: 23 January 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below